Atria Wealth Solutions Inc. Sells 11,476 Shares of Danaher Corporation $DHR

Key Points

• Atria Wealth Solutions Inc. has reduced its stake in Danaher Corporation by 55.1%, selling 11,476 shares and now owning 9,347 shares valued at approximately $1.85 million.
• Institutional investors hold 79.05% of Danaher's stock, with several hedge funds increasing their positions in recent months, contributing to the stock's market capitalization of $147.73 billion.
• Danaher recently announced a quarterly dividend of $0.32, representing an annualized yield of 0.6%, with its dividend payout ratio sitting at 27.23%.

Atria Wealth Solutions Inc. lowered its position in Danaher Corporation (NYSE:DHR - Free Report) by 55.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,347 shares of the conglomerate's stock after selling 11,476 shares during the quarter. Atria Wealth Solutions Inc.'s holdings in Danaher were worth $1,852,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of DHR. Nuveen LLC bought a new position in Danaher in the first quarter worth approximately $833,941,000. Invesco Ltd. grew its stake in Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after purchasing an additional 1,450,703 shares in the last quarter. Baird Financial Group Inc. grew its stake in Danaher by 290.6% in the first quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate's stock worth $295,550,000 after purchasing an additional 1,072,617 shares in the last quarter. Generation Investment Management LLP grew its stake in Danaher by 33.2% in the first quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate's stock worth $651,515,000 after purchasing an additional 791,662 shares in the last quarter. Finally, Parnassus Investments LLC boosted its position in Danaher by 23.3% during the 1st quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate's stock valued at $784,745,000 after acquiring an additional 722,636 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on DHR shares. Wells Fargo & Company dropped their target price on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 target price on Danaher in a research report on Tuesday, September 2nd. Robert W. Baird increased their target price on Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research report on Friday, July 18th. Barclays reaffirmed an "overweight" rating and set a $225.00 target price (up previously from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Finally, Bank of America dropped their target price on Danaher from $230.00 to $220.00 and set a "buy" rating on the stock in a research report on Monday, September 22nd. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $244.60.

Insider Transactions at Danaher

In related news, Director Teri List sold 2,778 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 11.10% of the stock is owned by company insiders.

Danaher Stock Up 0.1%

Danaher stock opened at $206.32 on Thursday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The stock has a market capitalization of $147.73 billion, a price-to-earnings ratio of 43.90, a PEG ratio of 2.94 and a beta of 0.77. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.41. The business has a fifty day moving average price of $201.18 and a 200-day moving average price of $197.19.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm's quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter last year, the business posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a $0.32 dividend. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher's dividend payout ratio (DPR) is 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.